125 related articles for article (PubMed ID: 21641259)
1. [Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis].
Vélez-Díaz-Pallarés M; Sánchez Cuervo M; Martínez-Pardo Casanova M; Bermejo Vicedo T
Farm Hosp; 2012; 36(1):55-6. PubMed ID: 21641259
[No Abstract] [Full Text] [Related]
2. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
3. Treatment of respiratory system (not just lung!) abnormalities in Mucopolysaccharidosis I.
Allen JL
J Pediatr; 2004 May; 144(5):561-2. PubMed ID: 15126984
[No Abstract] [Full Text] [Related]
4. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation.
Valayannopoulos V; de Blic J; Mahlaoui N; Stos B; Jaubert F; Bonnet D; Fischer A; de Lonlay P
Pediatrics; 2010 Nov; 126(5):e1242-7. PubMed ID: 20974778
[TBL] [Abstract][Full Text] [Related]
5. Massive macroglossia and airway obstruction after cleft palate repair.
Bell C; Oh TH; Loeffler JR
Anesth Analg; 1988 Jan; 67(1):71-4. PubMed ID: 3337349
[No Abstract] [Full Text] [Related]
6. Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy.
Yano S; Moseley K; Pavlova Z
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S53-7. PubMed ID: 19308670
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up.
Jurecka A; Marucha J; Jurkiewicz E; Różdżyńska-Świątkowska A; Tylki-Szymańska A
Pediatr Neurol; 2012 Dec; 47(6):461-5. PubMed ID: 23127271
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
[TBL] [Abstract][Full Text] [Related]
9. Alpha-L-iduronidase (laronidase; aldurazyme).
Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
[No Abstract] [Full Text] [Related]
10. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
11. [Respiratory control in deep cerebral coma: indications and limitations of tracheostomy].
Petterino E
Minerva Med; 1974 Oct; 65(76):3971-7. PubMed ID: 4423419
[No Abstract] [Full Text] [Related]
12. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
[TBL] [Abstract][Full Text] [Related]
13. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
[TBL] [Abstract][Full Text] [Related]
14. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.
Lin HY; Lin SP; Chuang CK; Chen MR; Chen BF; Wraith JE
J Inherit Metab Dis; 2005; 28(6):1146-8. PubMed ID: 16435211
[TBL] [Abstract][Full Text] [Related]
15. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I.
Anbu AT; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Feb; 29(1):230-1. PubMed ID: 16601901
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
[TBL] [Abstract][Full Text] [Related]
17. Laronidase hypersensitivity and desensitization in type I mucopolysaccharidosis: a case report.
Ensina LF; Aranda CS; de Lacerda AE; Camelo-Nunes I; Sole D; Martins AM; Castells M
Pediatr Allergy Immunol; 2014 Aug; 25(5):498-9. PubMed ID: 25313426
[No Abstract] [Full Text] [Related]
18. Laronidase opens door to treat other rare disorders.
Morrow T
Manag Care; 2004 Jun; 13(6):52-3. PubMed ID: 15259445
[No Abstract] [Full Text] [Related]
19. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
[TBL] [Abstract][Full Text] [Related]
20. Laronidase replacement therapy improves myocardial function in mucopolysaccharidosis I.
Harada H; Uchiwa H; Nakamura M; Ohno S; Morita H; Katoh A; Yoshino M; Ikeda H
Mol Genet Metab; 2011 Jul; 103(3):215-9. PubMed ID: 21482163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
